News 2018-01-31T19:27:01+00:00

moksha8 Pharmaceuticals and Daewoong Pharmaceuticals sign exclusive licensing agreement to commercialize Nabota (botulinum toxin) in Brazil

January 29, 2018

moksha8 Pharmaceuticals, announced today that it has entered into an exclusive licensing agreement with Daewoong Pharmaceuticals to commercialize botulinum toxin product Nabota in Brazil, the largest economy in Latin America.

“We are honored to be partnering with Daewoong Pharmaceuticals, one of the leading research- based companies in the world, in order to help expand the usage of Nabota in Latin America”, said Joel Barlan.

Under the new agreement, moksha8 will be responsible for marketing authorizations, market access, commercialization, distribution throughout Brazil.

moksha8 Brazil will adopt a two-track marketing strategy for Nabota, the company will be in charge of Nabota applied to medical conditions while cosmetic use will be taken care of by GC Aesthetic Brazil, the leading pure play female Aesthetic company.